Compare iShares Global Clean Energy ETF (ICLN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Global Clean Energy ETF trades at $17.28 (market cap $2.27B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 4.5× iShares Global Clean Energy ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 87 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| ICLN | XBI | |
|---|---|---|
Market Cap | $2.27B | $10.11B |
Volume | 6,845,064 | 12,903,266 |
52-Week High | $23.75 | $169.55 |
52-Week Low | $15.78 | $104.99 |
Typical Hold Time | 87 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.12, down 1.1% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF faces volatility compared to traditional energy peers, with a 57.2% maximum drawdown noted in recent analysis. Recent news highlights its 0.38% expense ratio and global clean energy exposure across 105 holdings.
Outlook remains mixed; clean energy benefits from geopolitical shifts boosting renewables demand, but high fees and underperformance versus fossil fuel ETFs pose risks. Investor sentiment is cautious amid sector rotation and competitive pressure from higher-yielding energy alternatives.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
